Unknown

Dataset Information

0

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement.


ABSTRACT: BACKGROUND:Suppression of the immunoinflammatory cascade by targeting interleukin 6 (IL-6) mediated effects constitutes a therapeutic option for chronic inflammatory diseases. Tocilizumab is the only IL-6 inhibitor (IL-6i) licensed for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), but also other agents targeting either IL-6 or its receptor are investigated in various indications. OBJECTIVE:To review published evidence on safety and efficacy of IL-6i in inflammatory diseases. METHODS:We performed systematic literature searches in Medline and Cochrane, screened EULAR and American College of Rheumatology meeting-abstracts, and accessed http://www.clinicaltrials.gov. RESULTS:Comprehensive evidence supports the efficacy of tocilizumab in RA in DMARD-naïve patients, and after DMARD- and TNFi-failure. Randomised comparisons demonstrate superiority of tocilizumab in JIA, but not ankylosing spondylitis (AS). Other indications are currently investigated. Additional IL-6i show similar efficacy; safety generally appears acceptable. CONCLUSIONS:IL-6i is effective and safe in RA and JIA, but not in AS. Preliminary results in other indications need substantiation.

SUBMITTER: Schoels MM 

PROVIDER: S-EPMC3595140 | biostudies-literature | 2013 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement.

Schoels Monika M MM   van der Heijde Désirée D   Breedveld Ferdinand C FC   Burmester Gerd R GR   Dougados Maxime M   Emery Paul P   Ferraccioli Gianfranco G   Gabay Cem C   Gibofsky Allan A   Gomez-Reino Juan Jesus JJ   Jones Graeme G   Kvien Tore K TK   Murakami Miho M   Nishimoto Norihiro N   Smolen Josef S JS  

Annals of the rheumatic diseases 20121110 4


<h4>Background</h4>Suppression of the immunoinflammatory cascade by targeting interleukin 6 (IL-6) mediated effects constitutes a therapeutic option for chronic inflammatory diseases. Tocilizumab is the only IL-6 inhibitor (IL-6i) licensed for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), but also other agents targeting either IL-6 or its receptor are investigated in various indications.<h4>Objective</h4>To review published evidence on safety and efficacy of IL-6i in inflamm  ...[more]

Similar Datasets

| S-EPMC3080043 | biostudies-literature
| S-EPMC2698849 | biostudies-literature
| S-EPMC7260093 | biostudies-literature
| S-EPMC8508938 | biostudies-literature
| S-EPMC8700244 | biostudies-literature
| S-EPMC5131649 | biostudies-literature
| S-EPMC3074355 | biostudies-literature
| S-EPMC7582977 | biostudies-literature
| S-EPMC6980732 | biostudies-literature